Kim N. Chi

Effect of abiraterone acetate plus prednisone on the pharmacokinetics of dextromethorphan and theophylline in patients with metastatic castration-resistant prostate cancer

A. Tolcher, B. Kaiser, A. Patnaik, 2012, Cancer Chemotherapy and Pharmacology.

A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer.

L. Seymour, S. Ellard, W. Walsh, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Castration-resistant prostate cancer: from new pathophysiology to new treatment targets.

F. Saad, T. Visakorpi, B. Tombal, 2009, European urology.

Defining the optimal treatment strategy for localized prostate cancer patients: a survey of ongoing studies at the National Cancer Institute of Canada Clinical Trials Group

F. Saad, C. Catton, K. Ding, 2008, Current oncology.

Temsirolimus in combination with carboplatin and paclitaxel in patients with advanced solid tumors: a NCIC-CTG, phase I, open-label dose-escalation study (IND 179).

E. Eisenhauer, A. Oza, H. Hirte, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group study IND195

E. Eisenhauer, J. Squire, S. Sridhar, 2015, Investigational New Drugs.

Preclinical and clinical activity of sunitinib in patients with cisplatin-refractory or multiply relapsed germ cell tumors: a Canadian Urologic Oncology Group/German Testicular Cancer Study Group cooperative study.

C. Bokemeyer, K. Oechsle, F. Mayer, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.